Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Decoding calcifications in breast cancer: Towards personalized medicine

2.

An ultrasound breast patch with conformability might help with early breast cancer detection.

3.

Healthy weight loss could lower your odds for cancer

4.

What Could This Exploratory 5-Year Survival Data in Adjuvant NSCLC Treatment Mean?

5.

Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot